Pfizer Inc vs WD 40 Company — how do they compare? Pfizer Inc trades at $27.83 (market cap $158.56B), while WD 40 Company trades at $211.17 (market cap $2.73B). The key difference: Pfizer Inc is far larger — about 58.1× WD 40 Company's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and WD 40 Company for 22 Days on average.
| PFE | WDFC | |
|---|---|---|
Market Cap | $158.56B | $2.73B |
Volume | 44,138,282 | 130,665 |
Sector | Health | Basic Materials |
52-Week High | $29.02 | $264.91 |
52-Week Low | $23.67 | $187.52 |
Typical Hold Time | 158 Days | 22 Days |
Enterprise Value | $210.06B | $2.79B |
Dividend Yield | 6.18% | 2% |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
WD-40 Company (WDFC) trades at $201.50, down 1.31% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with 55.82% gross margins and 13.22% net income margin, though recent earnings showed mixed results with two beats and one miss. Analyst consensus is mixed with 71% hold ratings despite a $475 price target, while institutional buying activity remains active. Recent news highlights strategic growth initiatives including global expansion and new CFO leadership.
The stock presents a cautious outlook with strong profitability offset by premium valuations (P/E 30.64) and technical weakness. Upside potential exists from the significant analyst price target premium, but risks include margin pressure from input costs and execution challenges in international markets. Current levels near support at $198-200 may offer entry points for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →